Hospitalization rates from respiratory syncytial virus (RSV) infection rose with age. Also, hospitalizations were more likely among nursing home residents and older adults with other health issues, ...

Scott and colleagues (Dec. 4 issue) 1 provide an updated synthesis of evidence about the effectiveness and safety of vaccines against Covid-19, respiratory syncytial virus (RSV) infection, and ...

FDA expansion of the Arexvy vaccine provides protection against RSV-related lower respiratory tract disease for at-risk adults aged 18 to 49 years. The Food and Drug Administration (FDA) has expanded ...

NEW YORK (PIX11) — November just began, but New York is already being hit with the three respiratory viruses: Influenza, COVID-19, and RSV. The latest report from the New York State Department of ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Every fall and winter, a familiar set of illnesses makes ...

Changes in the vaccine advisory process in the United States have disrupted immunization guidance, which reinforces the need for independent evidence review to inform decisions regarding immunization ...

—A recent study examined several broad categories of comorbidities in an attempt to determine which ones correlated with hospital admissions and lengths of stay associated with respiratory syncytial ...

This article is part of “Innovations In: RSV,” an editorially independent special report that was produced with financial support from MSD, Sanofi and AstraZeneca. Abigail Echo-Hawk believes in the ...

The Manitoba government is expanding its respiratory syncytial virus (RSV) protection program so that all infants in the ...